Inflammatory and Endothelial Dysfunction Biomarkers Predict Severe COVID-19 in Hospitalized Patients: Development of the CCBR Model

Background: Early identification of patients at risk of severe COVID-19 is critical for timely interventions. We evaluated a biomarker-based risk stratification model, the Composite COVID-19 Biomarker Risk (CCBR) score, integrating age and inflammatory biomarkers (IL-6, PAI-1, LDH, neutrophil-to-lymphocyte ratio [NLR], and ferritin) measured at hospital admission to support early clinical risk assessment. Methods: In this retrospective single-center study, 235 hospitalized COVID-19 patients were classified into non-severe (n = 106) and severe (n = 129) groups. Biomarkers were measured within 24 h of admission. The CCBR score (0–6 points) was constructed by assigning one point to each parameter exceeding predefined cut-off values derived from published clinical thresholds and confirmed using receiver operating characteristic (ROC) curve analysis (Youden’s index). Patients were stratified into three risk categories: low risk (0–1 points), moderate risk (2–3 points), and high risk (4–6 points). Associations between CCBR scores and clinical outcomes, including severe disease, acute respiratory failure, dyspnea, complications, and antibiotic use, were assessed using logistic regression and ROC analyses. Internal validation was performed using split-sample validation and bootstrap resampling. Results: CCBR scores were significantly higher among patients with severe disease (p > 0.001). Each 1-point increase in CCBR was associated with a 6.78-fold increase in the odds of severe disease (OR = 6.78, p < 0.001). ROC analysis demonstrated moderate to good discriminative performance for severe disease (AUC = 0.714) and acute respiratory failure (AUC = 0.751). Conclusions: The CCBR score represents a simple biomarker-based model integrating inflammatory and endothelial dysfunction markers for early stratification of COVID-19 severity. This approach may assist clinicians in identifying patients at higher risk of severe disease and acute respiratory failure early during hospitalization.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-05-08
DOI
https://doi.org/10.3390/biomedicines14051074
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inflammatory and Endothelial Dysfunction Biomarkers Predict Severe COVID-19 in Hospitalized Patients: Development of the CCBR Model

Andreea Mihaela Radu, Ștefan Sorin Aramă, Andrei Bogdan Văcărașu, Sebastian Ciobanu et al.
Biomedicines
COVID-19 Clinical Research Studies
article

Inflammatory and Endothelial Dysfunction Biomarkers Predict Severe COVID-19 in Hospitalized Patients: Development of the CCBR Model

Andreea Mihaela Radu, Ștefan Sorin Aramă, Andrei Bogdan Văcărașu, Sebastian Ciobanu, Aida-Isabela Adamescu, Adrian Gabriel Marinescu, Cătălin Tilișcan, Bogdan Popescu, Victoria Aramă
article en

Abstract

Background: Early identification of patients at risk of severe COVID-19 is critical for timely interventions. We evaluated a biomarker-based risk stratification model, the Composite COVID-19 Biomarker Risk (CCBR) score, integrating age and inflammatory biomarkers (IL-6, PAI-1, LDH, neutrophil-to-lymphocyte ratio [NLR], and ferritin) measured at hospital admission to support early clinical risk assessment. Methods: In this retrospective single-center study, 235 hospitalized COVID-19 patients were classified into non-severe (n = 106) and severe (n = 129) groups. Biomarkers were measured within 24 h of admission. The CCBR score (0–6 points) was constructed by assigning one point to each parameter exceeding predefined cut-off values derived from published clinical thresholds and confirmed using receiver operating characteristic (ROC) curve analysis (Youden’s index). Patients were stratified into three risk categories: low risk (0–1 points), moderate risk (2–3 points), and high risk (4–6 points). Associations between CCBR scores and clinical outcomes, including severe disease, acute respiratory failure, dyspnea, complications, and antibiotic use, were assessed using logistic regression and ROC analyses. Internal validation was performed using split-sample validation and bootstrap resampling. Results: CCBR scores were significantly higher among patients with severe disease (p > 0.001). Each 1-point increase in CCBR was associated with a 6.78-fold increase in the odds of severe disease (OR = 6.78, p < 0.001). ROC analysis demonstrated moderate to good discriminative performance for severe disease (AUC = 0.714) and acute respiratory failure (AUC = 0.751). Conclusions: The CCBR score represents a simple biomarker-based model integrating inflammatory and endothelial dysfunction markers for early stratification of COVID-19 severity. This approach may assist clinicians in identifying patients at higher risk of severe disease and acute respiratory failure early during hospitalization.

BiomedicinesVol. 14(5)
Carol Davila University of Medicine and Pharmacy (RO), Clinical Emergency Hospital Bucharest (RO), University of Medicine and Pharmacy of Craiova (RO), Infectious Diseases Institute (UG)
Reduced inequalities
Openalex Percentile: Top 4%
COVID-19 Clinical Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.